Jonathan Gerber to Mutation
This is a "connection" page, showing publications Jonathan Gerber has written about Mutation.
Connection Strength
1.319
-
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, Hutchinson L, Li S, Xie Y, Selove W, Cerny J, Gerber JM. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer. 2025 Jul 01; 131(13):e35950.
Score: 0.519
-
Patel SA, Gerber WK, Zheng R, Khanna S, Hutchinson L, Abel GA, Cerny J, DaSilva BA, Zhang TY, Ramanathan M, Khedr S, Selove W, Woda B, Miron PM, Higgins AW, Gerber JM. Natural history of clonal haematopoiesis seen in real-world haematology settings. Br J Haematol. 2024 May; 204(5):1844-1855.
Score: 0.475
-
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, Bindal P, Ramanathan M, Gerber JM, Cerny J, Patel SA. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025 Apr 15; 131(8):e35846.
Score: 0.128
-
Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A, Hutchinson L, Miron PM, Higgins AW, Ramanathan M, Gerber JM. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leuk Lymphoma. 2021 12; 62(14):3348-3360.
Score: 0.100
-
Gerber JM, Zeidner JF, Morse S, Blackford AL, Perkins B, Yanagisawa B, Zhang H, Morsberger L, Karp J, Ning Y, Gocke CD, Rosner GL, Smith BD, Jones RJ. Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes. Haematologica. 2016 05; 101(5):607-16.
Score: 0.068
-
Kennedy A, Patel S, Ramanathan M, Gerber J, Cerny J. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center. Ann Hematol. 2024 Mar; 103(3):1031-1033.
Score: 0.029